****

CANCER DIAGNOSIS PROGRAM TISSUE MICROARRAY SLIDES

PART 1: APPLICATION FOR SCIENTIFIC REVIEW

***COMPLETE THIS FORM TO REQUEST PRE-REVIEW OF YOUR PROPOSED USE OF CDP TMA SLIDES.***

***THIS IS STEP 1 OF A TWO STEP PROCESS.***

# DIRECTIONS

The Principal Investigator (PI) responsible for overseeing the project and controlling the laboratory and personnel who will receive, use and process the requested specimens should complete this form. A processing fee will be applied to each sample/aliquot to reimburse the CHTN for the processing and distribution of samples. Each PI is also responsible for all shipping costs

Any transfer of samples, aliquots, derivatives or associated clinical data to collaborating personnel or laboratories that are not under the direct supervision of the indicated PI requires the following:

* A written justification of the need to transfer the materials and benefit to the applicant’s research.
* A copy of the AGREEMENT FOR USE OF TISSUE MICROARRAY (TMA) SLIDES signed by the collaborator.

The CHTN does not supply samples to specimen banks whose purpose is distribution to third-party researchers; those researchers should be encouraged to apply to the CHTN directly.

The information in these forms is necessary in order to document correctly your request for TMA slides and to ensure that the CHTN operates within the guidelines of the National Cancer Institute. When submitting:

1. Please print neatly or type.
2. Patient identity is confidential. Samples on the TMA slides have been fully anonymized, and no additional donor or clinical information is available beyond what is provided with the TMA slides or made publicly available through the CHTN TMA website.

|  |  |
| --- | --- |
| *Mailing Address*:CHTN, Mid-Atlantic Division University of Virginia Dept. of Pathology Box 800904Charlottesville, VA 22908 | Mid-Atlantic DivisionTel: 434-924-9879Fax:434-924-9438CHTN-MidAtl@hscmail.mcc.virginia.eduDivision Coordinator: Rebecca BlackwellPI: Dr. Christopher Moskaluk |

1. Descriptions of currently available TMAs and fees are available at <http://chtn.sites.virginia.edu/>. **NOTE:** The CHTN does not provide or construct custom TMAs.
2. The PI is responsible for remission of processing fees to the Mid-Atlantic division for each TMA section provided, including fees for any additional services performed, and any shipping costs not directly billed to the applicant’s courier account.
3. Investigators requesting TMA slides from the CHTN should consult their local Institutional Review Board for policies and procedures for use of anonymous human tissue samples, such as are contained in the CHTN tissue microarrays. **NOTE:** The CHTN does not require documentation of IRB approval or exemption in order to request these materials.
4. **You must include all of the requested information. Incomplete applications will be returned for completion resulting in a delay in the evaluation of your request.**
5. Please mail, fax or e-mail this completed form and direct any questions to the Mid-Atlantic Division:

|  |
| --- |
| PRINCIPAL INVESTIGATOR INFORMATION |
| First Name:       Middle Name:       Last Name:      Salutation:       Degree:       Title:       Institution Type: [ ]  Academic/Government [ ]  Commercial [ ]  Non-profit**Mailing address:**Institution:      Department:       Address 1:      Address 2:      City:       State:       Zip code:       Country:      Tel#:       Alt. Tel#:       Fax#:      Email:       |

|  |
| --- |
| HOW DID YOU LEARN ABOUT THE CDP TISSUE MICROARRAYS |
| [ ]  Colleague[ ]  Scientific Publication or Meeting Specify:      [ ]  NCI Specimen Resource Locator[ ]  CHTN Website[ ]  Other Website Specify:      [ ]  Other Specify:       |

|  |
| --- |
| TYPE OF TMA REQUESTED AND NUMBER OF SLIDE SETS REQUESTED |
| A maximum of 10 slide sets per design may be requested. Please consult the detailed information about the design of the TMAs on the CHTN website at <http://chtn.sites.virginia.edu/>[ ]  CDP Breast Cancer Stage I Prognostic TMA # sets requested:       (1 set = 10 sections)[ ]  CDP Breast Cancer Stage II Prognostic TMA # sets requested:       (1 set = 8 sections)[ ]  CDP Breast Cancer Stage III Prognostic TMA # sets requested:       (1 set = 4 sections)[ ]  CDP Melanoma Progression TMA # sets requested:       (1 set = 4 sections) |

|  |
| --- |
| SCIENTIFIC RATIONALE |
| **Project Title:**      Provide a concise introduction to the project concluding with a brief statement of the hypothesis of the proposed research:     State the specific aims of the work to be carried out with the TMAs:     Provide a brief description of each marker to be evaluated:      |

|  |
| --- |
| SCIENTIFIC APPROACH |
| Briefly describe the technical approach (measurement techniques and reagents) you plan to use:     Describe your experience using this approach with human paraffin-embedded sections and/or TMA slides in your laboratory. Please provide data (published or preliminary) demonstrating that the specific antibodies/reagents and technical approach above have been validated in your own laboratory:      Describe the scoring system you plan to use:      Describe the positive and negative controls you plan to use:      Describe the statistical method(s) you will use to test the hypothesis and analyze the data:       |

|  |
| --- |
| **PROJECT INFORMATION** |
| The CHTN considers sources of funding and the Principal Investigator’s institution type when prioritizing specimen requests. Specimens are provided to investigators in the following priority order: 1. Peer reviewed funded investigators (including Federal and National laboratories).
2. New investigators and academic investigators developing new research projects.
3. Other investigators.

Please indicate the funding status of your proposed project:[ ]  Current peer-reviewed funding available for this project[ ]  Current institutional or other non-peer reviewed funding available for this project[ ]  Peer-reviewed funding has been requested to support this project\* Anticipated funding date:      [ ]  Other funding has been requested to support this project\* Anticipated funding date:      [ ]  Outcome of this scientific review will be used to support a funding request\* Anticipated funding date:       [ ]  Peer-reviewed [ ]  Other**\*Note that CDP TMA sections are not reserved and are a finite resource. Should you receive scientific approval for your request, the CHTN cannot guarantee that sufficient sections will be available to fulfill your request at a later date.**For additional information, please contact the Mid-Atlantic Division at (434) 924-9879 or email your query to the Mid-Atlantic Divsion (CHTN-MidAtl@hscmail.mcc.virginia.edu).  |

|  |
| --- |
| **PI CURRICULUM VITAE** |
|  [ ]  Please include a current copy of your C.V. with this submission |

Typed Name of PI Recipient

Signature of PI Recipient/Date